Molecular BiologyBritish Journal of CancerPeer-reviewed
The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer
Theodora A. Constantin, Anabel Varela‐Carver, Kyle K. Greenland…·Charlotte Lynne Bevan
This study investigates the antitumour activity of CT7001, a CDK7 inhibitor, in castration-resistant prostate cancer models, showing it inhibits proliferation and enhances enzalutamide efficacy.
29 citationstop 3%